Phase I study of phenylacetate administered twice daily to patients with cancer

Cancer

Volumn 75, Issue 12, 1995, Pages 2932-2938

  Thibault, Alain ^a   Samid, Dvorit ^a   Cooper, Michael R ^a   Figg, William D ^a   Tompkins, Anne C ^a   Patronas, Nicholas ^a   Headlee, Donna J ^a   Kohler, David R ^a   Venzon, David J ^c   Myers, Charles E ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

differentiation; glioma; pharmacokinetics; phenylacetate; prostate cancer

Indexed keywords

HYDROCORTISONE; PHENYLACETIC ACID; SURAMIN;

ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; FATIGUE; FEMALE; GLIOMA; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LEG EDEMA; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RASH; SARCOMA; SOLID TUMOR; SOMNOLENCE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PHENYLACETATES;

EID: 0029063579     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19950615)75:12<2932::AID-CNCR2820751221>3.0.CO;2-P     Document Type: Article

References (27)

1. Phenylacetic acid in human body fluids: high correlation between plasma and cerebrospinal fluid concentrations values
2. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria
3. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate
4. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation
5. Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate
6. Differentiation of cultured human melanoma cells induced by the aromatic fatty acid phenylacetate and phenylbutyrate
7. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer
8. Treatment of urea cycle disorders
9. Reporting results of cancer treatment
10. Clinical trials in prostatic cancer: methodology and controversies
11. Criteria for evaluating patient responses to treatment modalities for prostate cancer
12. The conjugation of phenylacetic acid in man, sub‐human primates and some non‐primate species
13. Synthesis of phenylacetylglutamine by human tissue
14. Serum prostate‐specific antigen: expanding its role as a measure of treatment response in patients with prostate cancer
15. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia
16. Enhancement of tumor immunogenicity by phenylacetate and derivatives: changes in surface antigens and tumor‐derived immunosuppressive factors [abstract]
17. Effect of the expression of transforming growth factor‐beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance
18. Biochemical strategy of cancer cells and the design of chemotherapy
19. Inhibition of brain and liver 3‐hydroxy‐3‐methylglutaryl‐CoA reductase and mevalonate‐5‐pyrophosphate decarboxylase in experimental hyperphenylalaninemia
20. Inhibition of chick brain cholesterogenic enzymes by phenyl and phenolic derivatives of phenylalanine
21. Effect of phenylalanine derivatives on the main regulatory enzymes of hepatic cholesterogenesis
22. Regulation of sterol synthesis in developing brains of normal and jimpy mice
23. An analysis of brain cholesterol and fatty acid biosynthesis
24. Studies on lipids in brain tumors. I. Occurrence and significance of sterol precursors of cholesterol in human brain tumors
25. Protein prenylation: a mediator of protein‐protein interactions
26. On the possible mechanism of phenylacetate neurotoxicity: inhibition of choline acetyltransferase by phenylacetyl‐CoA